G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis

British Journal of Cancer

Volumn 90, Issue 1, 2004, Pages 189-193

  Jezequel P ^a   Campion, L ^a   Joalland, M P ^a   Millour, M ^a   Dravet, F ^a   Classe, J M ^a   Delecroix, V ^a   Deporte, R ^a   Fumoleau, P ^a   Ricolleau, G ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Breast cancer; FGFR4 genotype; G388R mutation; Prognostic marker; Tyrosine kinase

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; TAMOXIFEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SCREENING; CANCER SURVIVAL; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RANK SUM TEST; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FIBROBLAST GROWTH FACTORS; GENOTYPE; HUMANS; MIDDLE AGED; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 10744225947     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601450     Document Type: Article

References (23)

1. Avet-Loiseau H, Li JY, Facon T, Brigaudeau C, Morineau N, Maloisel F, Rapp MJ, Talmant P, Trimoreau F, Jaccard A, Harousseau JL, Bataille R (1998) High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 58: 5640-5645
2. 388 allele. Cancer Res 62: 840-847
3. Breslow NE (1970) A generalized Kruskal - Wallis test for comparing k samples subject to unequal patterns of censorship. Biometrika 57: 579-594
4. Cappellen D, De Oliveira C, Ricol D, De Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thierry JP, Radvanyi F (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23: 18-20
5. Cavallaro U, Niedermeyer J, Fuxa M, Christofori G (2001) N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol 3: 650-657
6. Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA, Kuehl WM, Bergsagel PL (2001) Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumour progression in multiple myeloma. Blood 97: 729-736
7. Coope RC, Browne PJ, Yiangou C, Bansal GC, Walters J, Groome N, Shousha S, Johnston CL, Coombes RC, Gomm JJ (1997) The location of acidic fibroblast growth factor in the breast is dependent on the activity of proteases present in breast cancer tissue. Br J Cancer 75: 1621-1630
8. Cox DR, Oakes D (1984) Analysis of Survival Data. New York, NY: Chapman & Hall
9. Dixon WJ (1981) BMDP Statistical Software. Berkeley, CA: University of California
10. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa S (2002) Targeted expression of a human pituitary tumour-derived isoform of FGF receptor-4 recapitulates pituitary tumourigenesis. J Clin Invest 109: 69-78
11. Freedman LS (1982) Tables of numbers of patients required in clinical trials using the logrank test. Statist Med 1: 121-129
12. Green PJ, Walsh FS, Doherty P (1996) Promiscuity of fibroblast growth factor receptors. Bioessays 18: 639-646
13. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ (2000) Transformation and Stat activation by derivatives of FGFR1, FGFR3 and FGFR4. Oncogene 19: 3309-3320
14. Kaplan EL, Meier PI (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
15. La Rosa S, Sessa F, Colombo L, Tibiletti MG, Furlan D, Capella C (2001) Expression of acidic fibroblast growth factor (aFGF) and fibroblast growth factor receptor 4 (FGFR4) in breast fibroadenomas. J Clin Invest 54: 37-41
16. Muenke M, Schell U (1995) Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet 11: 308-313
17. Olson DC, Deng C, Hanahan D (1998) Fibroblast growth factor receptor 4, implicated in progression of islet cell carcinogenesis by its expression profile, does not contribute functionally. Cell Growth Differ 9: 557-564
18. Peto R, Peto J (1972) Asymptotically efficient rank invariant test procedures (with discussion). J R Statist Soc 135: 185-206
19. Powers CJ, Mc Leskey SW, Wellstein A (2000) Fibroblast growth factors, their receptors and signaling. Endocrine-Related Cancer 7: 165-197
20. Prentice RL (1978) Linear rank tests with right-censored data. Biometrika 65: 167-179
21. Shah RN, Ibbit JC, Alitalo K, Hurst HC (2002) FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1 alpha. Oncogene 21: 8251-8261
22. Tarone RE, Ware JH (1977) On distribution-free tests for equality of survival distributions. Biometrika 64: 156-160
23. Vajo Z, Francomano CA, Wilkin DJ (2000) The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev 21: 23-39